Van Damme, An http://orcid.org/0000-0002-7114-201X
Seront, Emmanuel http://orcid.org/0000-0003-4807-7472
Dekeuleneer, Valérie http://orcid.org/0000-0003-1210-6112
Boon, Laurence M. http://orcid.org/0000-0001-8273-3328
Vikkula, Miikka http://orcid.org/0000-0002-6236-338X
Article History
First Online: 15 June 2020
Compliance with Ethical standards
:
: No sources of funding were used to assist in the preparation of this review.
: An Van Damme and Valérie Dekeuleneer have no conflicts of interest that are directly relevant to the content of this article. Emmanuel Seront discloses the following interactions with the medical industry: (1) clinical trial support for VASE: Pfizer [slow-flow vascular anomalies (rapamycin)] and (2) clinical trial support for TRAMAV: Novartis [fast-flow vascular anomalies (trametinib)]. Laurence M. Boon discloses the following interactions with the medical industry: (1) clinical trial support for VASE: Pfizer [slow-flow vascular anomalies (rapamycin)]; (2) clinical trial support for TRAMAV: Novartis [fast-flow vascular anomalies (trametinib)]; (3) clinical advisory board: Venthera [slow-flow malformations (transdermal PI3K inhibitor)]; and (4) clinical advisory board: Pierre Fabre [infantile hemangiomas (beta-blockers)]. Miikka Vikkula discloses the following interactions with the medical industry: (1) research grant from Deciphera Pharmaceuticals [venous malformations (rebastinib)] and (2) scientific and clinical advisory boards: Venthera [slow-flow malformations (transdermal PI3K inhibitor)].
Free to read: This content has been made available to all.